Abstract Number: 1136 • 2017 ACR/ARHP Annual Meeting
Urate-Lowering Treatment and Risk of Total Joint Replacement in Patients with Incident Gout: A Population-Based Cohort and Nested Case-Control Study
Background/Purpose: This cohort study aimed to investigate the risk of total joint (hip/knee) replacement (TJR, THR and TKR) among patients with incident gout at initial…Abstract Number: 1137 • 2017 ACR/ARHP Annual Meeting
Urate Lowering to ACR-Recommended Targets Allows Significant Improvement of Severe Gout: A Monocentric Prospective Trial in Vietnam, Using a Systematic Treatment Protocol
Background/Purpose: Gout is frequent and severe in Vietnam, where urate-lowering drugs (ULD) are seldom used and many patients are treated only with traditional herbal medicine.…Abstract Number: 1138 • 2017 ACR/ARHP Annual Meeting
Investigation on Allele Frequency of Rs3117583 and Rs9263726 in Patients with Hyperuricemia or Gout
Background/Purpose: Allopurinol, effectively regulates and controls serum uric acid levels but may cause allopurinol-induced life-threating severe cutaneous adverse reaction (SCAR). Previous studies reported that single…Abstract Number: 1139 • 2017 ACR/ARHP Annual Meeting
Management of Gout – a Survey for Healthcare Providers in South Australia
Background/Purpose: Gout is a treatable arthritis and while the rate of gout in Australia has been steadily rising, drugs used to treat acute gouty arthritis…Abstract Number: 1140 • 2017 ACR/ARHP Annual Meeting
Gout Characteristics and Its Association with the Presence of Cardiovascular Disease: A Case-Control Study
Background/Purpose: Gout is an independent risk factor for any type of cardiovascular disease (CVD). The exact mechanism behind remains to be elucidated, but persistent crystal-related…Abstract Number: 1141 • 2017 ACR/ARHP Annual Meeting
Initial Results of a Clinical Study to Determine Whether a Tolerizing Regimen of Pegloticase Can Increase the Frequency of Subjects Having Sustained Lowering of Serum Urate
Background/Purpose: Pegloticase is a pegylated recombinant mammalian uricase approved for treatment of persons with chronic gout refractory to standard urate lowering therapy1. Despite initial reduction…Abstract Number: 1142 • 2017 ACR/ARHP Annual Meeting
A Case Control Study of Anakinra Use for Acute Gout in a VA Patient Cohort Reveals Association with East Asian Descent, High Urate Burden, and Increased Co-Morbidities and All-Cause Mortality
Background/Purpose: Effectiveness of the IL-1 receptor antagonist anakinra, in resolving flares of acute gout, has been reported in several case series. Here, studying a VA…Abstract Number: 1143 • 2017 ACR/ARHP Annual Meeting
The Patient Education for Gout Patients Ameliorate the Patients’ Satisfaction and Serum Uric Acid Level
Background/Purpose: The poor adherence to urate lowering therapy is due to a lack of appropriate information. This study performed to analyze the effect of education…Abstract Number: 1144 • 2017 ACR/ARHP Annual Meeting
Initiating Colchicine and Urate-Lowering Therapy Reduces Baseline Inflammation, and Improves Vascular Endothelial but Not Smooth Muscle Function in Gout Subjects: Resistance to Endothelial Improvement Among Patients with Cardiovascular Comorbidities
Background/Purpose: We have previously reported that patients with gout have impaired vascular endothelial and smooth muscle responsiveness, but whether initiating appropriate gout therapy ameliorates these…Abstract Number: 1145 • 2017 ACR/ARHP Annual Meeting
Effectiveness of a Multidisciplinary Gout Clinic on Timely Achievement of Serum Uric Acid Goals
Background/Purpose: The concept of a multidisciplinary gout clinic is relatively new in Singapore. Changi General Hospital launched such a clinic in 2014 to provide treat-to-target…Abstract Number: 1146 • 2017 ACR/ARHP Annual Meeting
Associations between Gout and Cancer in an Nhanes Cohort
Background/Purpose: Gout is the most common inflammatory disease in the United States (US), affecting more than 4% of the population. Although uric acid (UA) can…Abstract Number: 1147 • 2017 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome or Acquired Hemophagocytic Lymphohistiocytosis in Adults: Demographics, Clinical Characteristics, and Survivorship in an American Academic Medical Center
Background/Purpose: Macrophage Activation Syndrome, also known as acquired Hemophagocytic Lymphohistiocytosis in adults, is an immune-mediated systemic inflammatory state. It is associated with multisystem organ failure…Abstract Number: 1148 • 2017 ACR/ARHP Annual Meeting
Arthritis after Cancer Immunotherapy: Symptom Duration and Treatment Response
Background/Purpose: Checkpoint inhibitor immunotherapy has fundamentally changed the treatment for an actively expanding list of cancers, however its use is associated with immune related adverse…Abstract Number: 1149 • 2017 ACR/ARHP Annual Meeting
Clinical Implications of Ultrasonography (US) in Monitoring Disease Activity of Relapsing Polychondritis (RP) and Comparative Investigation By US between Auricle of RP, Repeated Trauma and Healthy Subject
Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disorder and might often be refractory. Therefore, the discovery of more convenient imaging modality than contrast-CT,…Abstract Number: 1150 • 2017 ACR/ARHP Annual Meeting
Ocular Involvement Is Exclusive with Genital Ulcer and Skin Lesion in the Early Phase of Behçet’s Disease: Nationwide Japanese Registration.
Background/Purpose: Behçetfs disease (BD) is a chronic inflammatory syndrome with features of multi-organ involvement and presents with mucocutaneous and ocular symptoms. We have previously found…
ACR Meeting Abstracts